Home›Ipamorelin›Legal status
Is Ipamorelin legal? FDA status and US regulatory standing
Current status
Barred from compounding. Ipamorelin is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound (status recorded ). Ipamorelin is an unapproved research peptide with no FDA bulk compounding authorization. While it has been offered by compounding pharmacies under various interpretations, federal compliance risk is elevated. Patients should verify current regulatory standing with their provider.
Primary source: www.fda.gov
Federal legal status
FDA approval status
Not FDA-approved as a drug. Not on the FDA 503A or 503B bulk substances lists. Ipamorelin's compounding status is contested — it was removed from the 503A consideration list and faces similar restrictions to other unapproved peptides.
Compounding pharmacy rules (federal)
Ipamorelin is not on the FDA-approved 503A or 503B bulk substances lists. Some compounding pharmacies have offered it historically, but FDA guidance suggests significant legal risk. Its status is often treated similarly to CJC-1295 and other non-listed peptides. Legal compounding under federal oversight is uncertain.
Also known as
NNC 26-0161
Status history
- Ipamorelin is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound. [source]
About Ipamorelin
Ipamorelin is a selective growth hormone secretagogue (GHSR agonist) and a pentapeptide. It stimulates growth hormone release with reportedly high selectivity — less stimulation of cortisol and prolactin than earlier GHRPs. Most evidence comes from animal studies.
Frequently asked questions
- Is ipamorelin legally available from compounding pharmacies?
- Ipamorelin is not on the FDA bulk substances lists for 503A or 503B compounding. Some pharmacies have offered it, but federal compliance is uncertain. The regulatory environment has tightened since 2021. Patients should ask their provider for explicit documentation of the legal basis.
State-level notes
Compounding and prescribing rules are administered by state pharmacy boards and vary by state. Federal FDA status (above) applies nationwide.
Content review: Regulatory status is sourced from the linked primary records and reviewed by the PeptideBase editorial team. This page is educational — not legal or medical advice. Last reviewed: .